Substance / Medication

Caplacizumab

Overview

Active Ingredient
caplacizumab
RxNorm CUI
2110605

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Peng Jia-Ying, Wang Si-Yang, Chen Miao-Qi et al. · Blood Coagul Fibrinolysis · 2024
PMID: 38874905Meta-Analysis
Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He Jingyi, Qi Jiaqian, Han Haohao et al. · Expert Rev Hematol · 2023
PMID: 37045600Meta-Analysis
Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Djulbegovic Mia, Tong Jiayi, Xu Alice et al. · Blood Adv · 2023
PMID: 36053773Meta-AnalysisFull text (PMC)
Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia.
Soto-Mora Jahir A, Gómez-Espitia Lina M, Lasalvia Pieralessandro et al. · Int J Technol Assess Health Care · 2023
PMID: 37476982Meta-AnalysisFull text (PMC)
Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.
Giannotta Juri Alessandro, Artoni Andrea, Mancini Ilaria et al. · J Thromb Haemost · 2025
PMID: 39549837Observational
Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program.
de Oliveira Boechat Tiago, de Holanda Farias João Samuel, Ribeiro Eduardo Flávio Oliveira et al. · Ann Hematol · 2023
PMID: 37055582ObservationalFull text (PMC)
Real-world experience with caplacizumab in the management of acute TTP.
Dutt Tina, Shaw Rebecca J, Stubbs Matthew et al. · Blood · 2021
PMID: 33150355Observational
Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era.
Mirouse Adrien, Legriel Stéphane, Dumas Guillaume et al. · Crit Care Med · 2021
PMID: 34166282Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Caplacizumab (substance)
SNOMED CT
784411004
UMLS CUI
C3713057
RxNorm CUI
2110605

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.